Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
159M
-
Number of holders
-
228
-
Total 13F shares, excl. options
-
89.6M
-
Shares change
-
+668K
-
Total reported value, excl. options
-
$748M
-
Value change
-
-$269M
-
Put/Call ratio
-
1.18
-
Number of buys
-
138
-
Number of sells
-
-99
-
Price
-
$8.36
Significant Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) as of Q3 2023
315 filings reported holding TGTX - TG THERAPEUTICS, INC. - COMMON STOCK as of Q3 2023.
TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 228 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89.6M shares
of 159M outstanding shares and own 56.38% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13.5M shares), BlackRock Inc. (9.99M shares), STATE STREET CORP (9.82M shares), Paradigm Biocapital Advisors LP (3.62M shares), WELLINGTON MANAGEMENT GROUP LLP (3.1M shares), GEODE CAPITAL MANAGEMENT, LLC (2.93M shares), Soleus Capital Management, L.P. (2.88M shares), TWO SIGMA INVESTMENTS, LP (2.34M shares), MILLENNIUM MANAGEMENT LLC (2.02M shares), and Opaleye Management Inc. (1.89M shares).
This table shows the top 228 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.